Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 11/20 | 0.63 |
| ▸ | EGFR | P00533 | 9/20 | 0.63 |
| ▸ | ABL1 | P00519 | 8/20 | 0.63 |
| ▸ | ABL2 | P42684 | 8/20 | 0.63 |
| ▸ | LCK | P06239 | 5/20 | 0.57 |
| ▸ | KDR | P35968 | 5/20 | 0.57 |
| ▸ | TEK | Q02763 | 4/20 | 0.57 |
| ▸ | LYN | P07948 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | RGS12 | O14924 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | FYN | P06241 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20351599 | 0.95 | SRC (0.61) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL20351793 | 0.89 | SRC (0.60) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL28669572 | 0.89 | EGFR (0.56) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL28669568 | 0.89 | EGFR (0.56) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL20351775 | 0.89 | SRC (0.52) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL20351711 | 0.88 | SRC (0.52) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL18044541 | 0.87 | SRC (0.81) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL2072372 | 0.87 | SRC (0.60) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL20351548 | 0.86 | SRC (0.49) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL20351610 | 0.85 | RIPK2 (0.47) | SRCEGFRABL1ABL2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018121228-A1 | COMPOUND HAVING AXL INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR AND USE THEREOF | 中国科学院上海药物研究所 | 2018-07-05 | — | — | WO | disclosed |
| EP-3067356-B1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-9586967-B2 | Pyrrolo pyrimidine derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3067356-A1 | PYRROLO PYRIMIDINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-7863444-B2 | 4-aminopyrrolopyrimidines as kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-01-04 | — | — | US | disclosed |
| EP-1114052-B1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBOTT GMBH & CO KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264579-A1 | PYRROLO PYRIMIDINE DERIVATIVE | AXL, FLT3, TYRO3 | SRC 26/4885EGFR 80/4885ABL1 39/4885 |
| US-20030187001-A1 | 4-AMINOPYRROLOPYRIMIDINES AS KINASE INHIBITORS | LCK, PPP5C, DUSP1 | SRC 89/4885EGFR 294/4885ABL1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.